Veraxa Biotech Holding AG (VRXA) Form 424B5 — Aug 10, 2026
Veraxa Biotech AG filed a prospectus supplement registering the resale of up to 120,295,385 ordinary shares by selling securityholders — including 99,695,385 shares issued to directors, officers and affiliates in the June 2026 business combination — plus 6,786,739 private warrants and up to 19,436,739 shares issuable on warrant exercise. The company will receive no proceeds from any sale of securities by the selling securityholders; its only potential proceeds come from cash warrant exercise at $11.50 per share, far above the $1.99 closing price on August 7, 2026, making exercise unlikely.
Key figures
- Debt Amount
- 27500000
- Gross Proceeds
- $0 to the Company from Selling Securityholder sales
- Offering Price
- No fixed offering price (prevailing market prices); Warrant exercise price US$11.50 per share
- Shares Offered
- Up to 120,295,385 Ordinary Shares by Selling Securityholders, plus up to 6,786,739 Private Warrants and up to 19,436,739 Ordinary Shares issuable upon Warrant exercise
- Shares Outstanding
- 141407813
- Cantor fee shares
- 3500000
- Accumulated deficit
- CHF 66.6 million as of December 31, 2025
- High trail note term
- 15 months, amortizing monthly beginning six months after June 15, 2026 closing
- Lincoln park facility usd
- 50000000
- Presentation exchange rate
- 1 CHF = USD 1.24
- Warrant exercise price usd
- 11.5
- Warrant close 2026 08 07 usd
- 0.096
- Lincoln park commitment shares
- 340910
- Ordinary share close 2026 08 07 usd
- 1.99
- Cantor deferred underwriting fee usd
- 12045000
- Resale shares from spac class b conversion
- 6100000
- Shares under htc note and high trail warrant
- 11000000
- Resale shares from business combination insiders
- 99695385
Price after filing
Close on the filing date to close N calendar days later (from $1.85). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.